Following the candidate gene approach we analyzed the CD40L, CD40, BLYS and CD19 genes that participate of B-cell co-stimulation, for association with pemphigus foliaceus (PF), an organ-specific autoimmune disease, characterized by the detachment of epidermal cells from each other (acantholysis) and presence of autoantibodies specific for desmoglein 1 (dsg1), an epidermal cell-adhesion molecule. The disease is endemic in certain regions of Brazil and also is known as fogo selvagem. Complex interactions among environmental and genetic susceptibility factors contribute to the manifestation of this multifactorial disease. The sample included 179 patients and 317 controls. Strong significant association was found with CD40LÀ726T4C (odds ratio, OR ¼ 5.54 and 0.30 for T þ and C þ genotypes, respectively). In addition, there were significant negative associations with CD40 À1T (OR ¼ 0.61) and BLYSÀ871T (OR ¼ 0.62) due to the decrease of the frequency of both homo-and heterozygotes in the patient group. No associations were found with variants of CD19 gene. Gene-gene interactions were observed between CD40 and BLYS, and between CD40L and BLYS. So, the dominant protective effects of CD40LÀ726C and of CD40 À1T only manifest in BLYSÀ871T þ individuals, and vice versa. We conclude that genetic variability of CD40L, CD40 and BLYS is an important factor for PF pathogenesis.
Introduction
Although autoimmune diseases are considered to be driven by T cells, emerging data suggest that B cells are more important in these diseases than previously thought. 1 B cells respond to numerous stimuli that regulate negative selection in the bone marrow, the generation of humoral immune response in the periphery, and the establishment and maintenance of tolerance and memory. The outcome of these developmental responses is dependent of signaling thresholds through the B-cell antigen receptor (BCR) complex. An array of cell-surface molecules augments or diminishes the stimulatory signals during B-cell development as well as during responses to self-and foreign antigens. Small changes in these molecules' expression have dramatic effects on signaling thresholds within B cells, which in turn have considerable impact on the balance between humoral immune response and tolerance induction. 2 So, polymorphisms in the coding and/or the regulatory regions of the corresponding genes may influence immune responses.
T-B cell interaction mediated by CD40ÀCD40L provides the co-stimulatory signal for B-cell proliferation and differentiation, immunoglobulin class switching, antibody secretion, prevention of apoptosis in germinal-center B cells, affinity maturation and the generation of memory B cells. The CD40 molecule (tumor necrosis factor receptor 5, TNFR-5), a member of the TNF receptor family, is expressed on hematopoietic (B cells, dendritic cells and macrophages) and nonhematopoietic cells (thymic epithelial cells, vascular endothelial cells, smooth muscle cells, fibroblasts and keratinocytes). 3, 4 CD40 is a major co-stimulatory molecule required for the development of humoral and cell-mediated immune responses. Its ligand, CD40L (also known as CD154, TRAP, TNFSF5, CD40LG) is expressed on activated helper T cells. CD40L has also been shown to help stimulation of T-cell-mediated immune response by activating antigen-presenting cells, which in turn express higher levels of B7 (CD80 and CD86) proteins. In vivo blockade of CD40 or CD40L suppresses the induction of autoimmune diseases in murines (for a review, see Howard and Miller 5 ), including in pemphigus vulgaris model mice. 6 Therefore, blockade of the CD40-CD40L interaction has been considered an attractive immunoregulatory strategy for the suppression of antibody production in autoimmune diseases.
B-lymphocyte stimulator (BLYS, also known as BAFF, TALL-1, zTNF4, TNFSF13B) is member of tumor necrosis factor (TNF) superfamily, expressed on T cells, monocytes, macrophages and dendritic cells, and three different receptors for BLYS are differentially expressed primarily on B cells. [7] [8] [9] BLYS is a potent B-cell co-stimulator and promotes B-cell differentiation, proliferation and survival. 1 Transgenic mice overexpressing BLYS develop symptoms characteristic of systemic lupus erythematosus (SLE). 10 Increase of BLYS level was reported in the serum or synovial fluid for several human autoimmune diseases. [11] [12] [13] These evidences link BLYS to pathological autoimmunity.
CD19 is a B-lymphocyte member of the immunoglobulin superfamily expressed by early pre-B cells from the time of heavy chain rearrangement until plasma cell differentiation. CD19 associates with CD21, CD81 and Leu13 on the B-cell surface to form the B-cell co-receptor complex, which acts as a modulator of BCR signaling. This complex is categorized among the 'response regulation' class of receptors, which determine the magnitude and outcomes of BCR signals. In mice, CD19 deficiency results in hypogammaglobulinemia and generates modest immune responses. [14] [15] [16] In contrast, overexpression of CD19 in transgenic mice results in B cells that are hyperresponsive to transmembrane signals and have elevated humoral immune responses. Further, the level of CD19 expression was shown to be approximately 20% higher in patients with systemic sclerosis. 17 So, CD19 seems to function as a general regulator that defines signaling thresholds critical for expansion of the peripheral B-cell pool. 18 On the basis of these observations, CD40L, CD40, BLYS and CD19 can be considered strong candidates genes for susceptibility to autoimmune diseases. This prompted us to investigate the possible associations between polymorphisms of these genes with endemic pemphigus foliaceus (PF). PF is an organ-specific autoimmune disease, also known as fogo selvagem (meaning wild fire), characterized by intraepidermal blisters due to the loss of adhesion among keratinocytes. The hallmark of this disease is the presence of antibodies, mainly of the IgG4 subclass, specific for the extracellular domain of desmoglein 1 (dsg1), an epidermal celladhesion molecule. The disease is preceded by a nonpathogenic antibody response mostly of the IgG1 subclass. A significant rise in the antibody titers, predominantly IgG4, correlates with the onset of the clinical manifestations. 19, 20 However, the pathogenicity seems not to be associated to the subclass, but to the fine specificity of the autoantibodies. 19 Histopathologically, the blisters are characterized by the detachment of epidermal cells from each other, a process called acantholysis. The exact mechanism of acantholysis is not yet understood.
The disease is endemic in South America and reaches its highest incidence in some regions of Brazil: 25-35 cases per million per year. 21 The unique epidemiological features of PF strongly suggest that it has an environmental trigger. Endemic foci are usually located in rural areas of Brazil and most patients are children and young adults, living near to rivers within the flying range of certain hematophagous insects, especially of the Simuliidae family (black flies). This led to the hypothesis that these insects may be the vectors of infectious agents or sensitize individuals to its salivary proteins. 19 The involvement of genetic factors in endemic PF has been suggested by familial clustering and by the high proportion of individuals living in the endemic foci who do not manifest the disease. 20 In the search for genes contributing to interindividual differences of disease susceptibility, clear-cut and strong associations to certain HLA-DRB1, DQA1 and DQB1 alleles were reported. [22] [23] [24] Associations were found also with interleukin 6, interleukin 4 25 and programmed cell death 1 genotypes 26 but not with the TNF, lymphotoxin-a, DSG1 polymorphisms, cytotoxic T-lymphocyte antigen-4 gene, BAX and TP53 polymorphisms. [27] [28] [29] [30] This is typical for multifactorial (complex) diseases, with several genetic and environmental factors involved in etiology and pathogenesis, and justifies the search for other genes modulating the susceptibility to PF.
We examined the possible associations between single nucleotide polymorphisms (SNPs) and short tandem repeats (STR) of the CD40L, CD40, BLYS and CD19 genes with variable susceptibility/resistance to endemic PF, by comparing the allelic, genotypic and allele carrier frequencies in unrelated patients with those of healthy individuals. Besides, we analyzed interactions between these genes through stratified analysis.
Results

Individual analysis
Because CD40L is located in X chromosome, association analyses of the À726T4C SNP were performed for men and women separately. Comparisons of the allele frequencies between the Euro-and the Afro-Brazilian population strata revealed no significant differences (patients: P ¼ 0.193, controls: P ¼ 0.167). Therefore, analysis was carried out also for the total population sample. Statistical analysis revealed significant differences in allelic, genotypic and allele carrier frequencies in total sample (Table 1a) . The frequency of allele T was increased (odds ratio, OR ¼ 3.69) accompanied by a decrease of allele C in patients (OR ¼ 0.27; Po10 À4 ). The C allele carriers (C þ individuals) were underrepresented in patients (OR ¼ 0.28; P ¼ 0.001) due to a decrease of both the C/C (OR ¼ 0.06; P ¼ 0.007) and the T/C (OR ¼ 0.35; P ¼ 0.005) genotypes. In fact, genotype C/C was not seen in any of the patients while its frequency in the control group was 7.3%. These same associations were observed in both EU and AF strata. When statistical significance was not reached in the AF stratum, a consistent tendency to the same direction was found. Because the allele frequencies were similar in men and women (patients: P ¼ 0.786, controls: P ¼ 0.509) and association analysis in both sexes gave essentially the same results (Table 1a and b), data from women and men were combined. The results were very similar to those found for sexes separately: the frequency of T allele was increased (OR ¼ 3.65) accompanied by a decrease of C allele in patients (OR ¼ 0.27; Po10 À6 ); the C allele carriers were underrepresented in patients (OR ¼ 0.30; Po10
À6
) and T allele carriers were overrepresented (OR ¼ 5.54; P ¼ 3.4 Â 10 À4 ) (Table 1c) . These results indicate that the CD40LÀ726T4C SNP is strongly associated with variable susceptibility to PF and the disease risk is decreased by the presence of allele C and increased by homozygosity, in women, or hemizygosity, in men, of allele À726T.
The allelic, genotypic and allele carrier frequencies of CD40À1C4T were compared between the patients and the controls in both the Euro-Brazilian and the AfroBrazilian population strata and in the total sample (Table 2) . A statistically significant (P ¼ 0.037) difference of allelic frequency was found between the patients and control groups in the EU but not in the AF stratum. The T allele was underrepresented among the patients. Because the EU/AF proportion is higher among controls (3.4:1) than among patients (1.4:1) and because the difference between the genotypic frequencies of the Afro-and EuroBrazilian population strata is not negligible in controls, we re-analyzed the merged sample after adjustment for this disproportion. The difference between patients and controls was significant and the ORs were similar to those observed in the EU and AF strata (for allelic frequencies P ¼ 0.012; OR ¼ 1.63 and 0.61 for alleles C and T, respectively and for T allele carriers, P ¼ 0.034; OR ¼ 0.61). From these results, we considered that CD40À1C4T may be associated with variable susceptibility to PF.
For BLYSÀ871C4T because the Euro-and the AfroBrazilian population strata did not differ significantly regarding allelic frequencies (patients: P ¼ 0.081, controls: P ¼ 0.118), the two subsamples were merged and association analysis was performed also for the whole sample. Statistical analysis revealed significant differences in allelic, genotypic and allele carrier frequencies in the total sample ( Table 3 ). The T allele was underrepresented in patients (P ¼ 0.011) due to a decrease both the T/T (OR ¼ 0.51; P ¼ 0.039) and the T/C (OR ¼ 0.66; P ¼ 0.047) genotypes and consequently of T allele carriers (OR ¼ 0.62; P ¼ 0.010). So, also that polymorphism may influence susceptibility to PF.
A total of 117 (106 EU, 11 AF) control individuals were genotyped for BLYS c.313G4A. The A allele was found in only one heterozygote individual (0.4%). Because of the lack of polymorphism, variation at this nucleotide was not used for disease association analyses.
Comparisons of the allelic, genotypic and allele carrier frequencies of CD19 IVS-14C4T between the patients and the controls did not reveal any statistically significant difference neither in Euro-Brazilians nor in AfroBrazilian or the whole sample ( Table 4 ). The Euro-and Afro-Brazilian strata did not differ significantly for allele frequencies (patients: P ¼ 0.632; controls: P ¼ 0.368); therefore analysis for the whole sample was possible. The results show that this polymorphism is not an important factor for PF pathogenesis in the population analyzed.
Allelic and allele carrier frequencies of the CD40L 3 0 UTR(CA)n did not reveal any noteworthy difference between patients and controls (Table 5 ). Only women were analyzed and statistical tests were not carried out for the AF stratum because of the small number of individuals in each class. For the CD19 3 0 UTR(CA)n, the whole sample was analyzed after correction for the different contributions of Euro-and Afro-Brazilians to the control and patient groups (Table 6 ). Statistical analysis revealed significant differences in allelic and allele carrier frequencies of the CD19 3 0 UTR 336 allele (Table 6 ). When we grouped alleles with higher and lower numbers of repetitions of the CD40L and CD19 STR, no statistically significant difference was found (data not shown). Association analysis considering the haplotypes of CD40L and of CD19, formed by the respective SNPs and 3 0 UTR(CA)n STRs, did not reveal any statistically significant difference between patients and controls as well (data not shown). Table 1 Allelic, genotypic and allele carrier frequencies of the CD40LÀ726(T,C) variants in patients and controls Abbreviations: CI, confidence interval; H-W, Hardy-Weinberg equilibrium probability values; OR, odds ratio.
Pemphigus foliaceus and B-cell co-stimulatory genes D Malheiros and ML Petzl-Erler
Significant linkage disequilibrium was observed between CD19 IVS-14C and CD19 3 0 UTR 334 alleles (D 0 ¼ 0.687; P ¼ 0.002). No significant linkage disequilibrium was found between the CD40L variants.
Adherence to the Hardy-Weinberg equilibrium expectation was tested for each SNP and STR in both subsamples and the total sample (Tables 1-6 ).
Compound analysis
The alleles at different loci may interact, increasing or decreasing susceptibility to diseases in comparison to the effect of variations at the individual loci. When genes are individually associated with the diseases, the genotypes of another locus may modify the disease risk, and the effect can be measured by the change of the OR. Even if Table 2 Allelic, genotypic and allele carrier frequencies of the CD40À1(C,T) variants in patients and controls
Total
Euro-Brazilian Afro-Brazilian Pemphigus foliaceus and B-cell co-stimulatory genes D Malheiros and ML Petzl-Erler variants of a gene are not individually associated with a disease, certain compound genotypes may still be influencing susceptibility. This is possible because of gene interaction, or epistasis. We looked for combinations of CD40, CD40L, BLYS and CD19 genotypes 2 Â 2 and wondered whether variants of one locus would be equally distributed in the different population subgroups, stratified according to genotypes of the second locus and vice versa. Only SNPs were considered for this analysis. Gene interaction was revealed when compound genotypes of CD40À1C4T and BLYSÀ871C4T; and of CD40LÀ726T4C and BLYSÀ871C4T were analyzed. According to individual analysis, the presence of allele CD40À1T (OR ¼ 0.61; P ¼ 0.034; Table 2 ) and of BLYSÀ871T (OR ¼ 0.62; P ¼ 0.010; Table 3 ) has dominant protective effects. Individuals presenting both the Tables 1 and 3 ). In agreement with this evidence of epistasis between CD40L and BLYS, the dominant protective effect of CD40L C only manifests in BLYS T þ individuals (OR ¼ 0.14; P ¼ 2 Â 10
À4
), that is, genotypes CD40L C/C and C/T do not seem to have a significant effect in BLYS C/C individuals (OR ¼ 0.48; P ¼ 0.104; Table 8c and d) . Equally, the dominant protective effect of BLYS T only manifests in CD40L C þ individuals (OR ¼ 0.30; P ¼ 0.076), that is, genotypes BLYS T/T and T/C do not have any effect in CD40L T/T individuals (OR ¼ 1.03; P ¼ 1; Table 8e and f).
The effects of BLYS T þ in CD40 T þ and in CD40L C þ individuals are near to the statistical significance limit (P ¼ 0.057 and 0.076, respectively). This is probably due and with genotypes BLYSÀ871C/C; CD40-1C/C are compared to those of controls with the same two compound genotypes. The T+; T+ genotype is less common (OR ¼ 0.41) and, conversely, the C/C; C/ C genotype is more common (OR ¼ 2.43) in patients than in controls and the difference is significant (P ¼ 0.001; 95% CI 0.24-0.72 and 1.39-4.24, respectively). In addition, the effect of the compound genotypes T+; T+, as revealed by the OR, is more extreme than the effect of each of these genotypes individually (see Tables 2 and 3) . The analyses A, B, C and E all reveal the protective effect of the compound T+; T+ genotype, although the strength of this effect varies according of the compound genotype taken as reference (second line in each analysis), whereas the analyses D and F show that neither CD40À1T+ nor BLYSÀ871T+ in the absence of each other has a significant protective effect. Detailed explanation is given in Results-Compound analysis. BLYS and CD40L compound genotypes; for example, in analysis (A), the numbers of patients with genotype BLYSÀ871T+; CD40LÀ726C+ and with genotypes BLYSÀ871C/C; CD40LÀ726T/T are compared to those of controls with the same two compound genotypes. The T+; C+ genotype is less common (OR ¼ 0.14) and, conversely, the C/C; T/T genotype is more common (OR ¼ 6.92) in patients than in controls and the difference is significant (P ¼ 8 Â 10À5; 95% CI 0.05-0.44 and 2.25-21.26, respectively). In addition, the effect of the compound genotype T+; C+, as revealed by the OR, is more extreme than the effect of each of these genotypes individually (see Tables 1 and 3 ). The analyses A, B, C and E all reveal the protective effect of the compound T+; T+ genotype, although the strength of this effect varies according of the compound genotype taken as reference (second line in each analysis), whereas the analyses D and F show that neither CD40LÀ726C+ nor BLYSÀ871T+ in the absence of each other has a significant protective effect. Detailed explanation is given in Results-Compound analysis.
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to the small size of subsamples, because BLYSÀ871T, CD40À1T and CD40LÀ726C are the less frequent alleles. The analyses of the CD40ÀCD40L, CD40ÀCD19 and CD40LÀCD19 compound genotypes did not reveal gene interactions in the studied population, because in the sample stratified according to the predisposing alleles and genotypes of the first gene, alleles of the second gene were found at frequencies not differing significantly from those seen in the whole, not subdivided sample (results not shown). However, interaction between these genes should not be discarded, because for several less frequent genotypes, stratified analysis was not possible due to the small size of subsamples and the consequent low statistical power.
Discussion
The wide range of biological activities attributed to CD40, CD40L, BLYS and CD19 and the functional consequences of the variability of their genes suggest the participation of these molecules in the pathogenesis of several diseases, including pathological autoimmunity. It is reasonable to suppose that the genetic variability of these molecules may correlate with interindividual variation of autoimmune disease susceptibility. These molecules might participate in various stages of PF pathogenesis, because they are fundamental in humoral immune responses.
Expression of CD40L on T cells is transient, with the ligand being present on activated mature T cells but not on resting T cells. The sensitive regulation of CD40L expression suggests that polymorphisms in the 5
0 and 3 0 regulatory regions may be important for the immune response. This prompted us to investigate the À726T4C SNP in the 5 0 regulatory region and a dinucleotide repeat in the 3 0 untranslated region (UTR) for association with PF. Sabeti et al. 31 found a small significant reduction in risk for severe malaria (OR ¼ 0.52; P ¼ 0.002) in men hemizygous for CD40LÀ726C. Analysis by transmission disequilibrium test confirmed the association. A similar but not significant trend was found in women. In endemic PF the disease risk is decreased by the presence of C allele, and this effect is much stronger than that observed for malaria. The protective effect is similar in homo-and heterozygosity, suggesting a dominant effect of the C allele. The overall consistency of the differences between women and men, and Euro-Brazilian and AfroBrazilian subsamples of patients and controls in the present study is noteworthy. Besides, the strength of the association is similar to that seen for associations with MHC class II genes, which have a pivotal function in most autoimmune diseases, including in PF. 24 To date, other autoimmune diseases were not analyzed for association with the CD40LÀ726T4C SNP. Chadha et al. 32 examined the association of SNPs and haplotypes of the CD40 and CD40L genes in SLE and no evidence of association was found in European families. Although the segment analyzed included nucleotide À726, this SNP was not tested. In the 5 0 region of CD40L there are three putative NFAT transcription factor binding sites, the most distal one being about 760 bp upstream of the transcription start site. 33 If this variation can change affinity of these proteins needs to be clarified. Regarding the microsatellite in 3 0 UTR of CD40L, Citores et al. 34 demonstrated that the group of longer alleles is associated with SLE, accompanied by a more prolonged protein expression in activated lymphocytes from controls. Our results showed no evidence of associations between PF susceptibility and individual alleles or the allele carrier status and also not for grouped alleles. So, this microsatellite does not seem to influence the pathogenesis of PF. Taken together the results of the present study reveal that CD40L is an important gene for further investigation in relation to PF susceptibility. A polymorphism has been reported for the CD40 gene, in the Kozak sequence of the 5 0 UTR at nucleotide À1C4T. 35 Association studies have been performed for Graves' disease (GD), multiple sclerosis (MS) and myasthenia gravis (MG). Two independent studies, in the United States and Korea, showed a significant increase in the frequency of the CD40À1 C/C genotype in GD patients. 35, 36 Although these results could not be replicated clearly in three subsequent large case-control studies in the United Kingdom and Poland, [37] [38] [39] metaanalysis suggested that the C/C genotype is associated with sporadic GD. 39, 40 No association of disease susceptibility or disease course in MS and MG was found with the CD40À1C4T polymorphism. However, functional studies revealed significant expression of CD40 mRNA and protein in the thyroid (target tissue in GD) but not in skeletal muscle (target tissue in MG). 41 Besides, when functional effects of the different genotypes were analyzed in MS, although the cell-surface expression of CD40 did not differ within the genotypes, carriers of T allele showed a trend for a lower stimulatory index compared with individuals with the C/C genotype. 42 In summary, in all studies, there is a small reduction of the T allele and increase of the C allele (mostly only in the homozygous state) frequency among the patients. In the present study, the CD40À1T allele and T allele carrier status were significantly associated with altered susceptibility to PF, consistent with a dominant or incompletely dominant protective effect of this allele. Accordingly, the CD40À1 C/C genotype is associated with increased susceptibility to PF (P ¼ 0.025; OR ¼ 1.65 (CI ¼ 1.06-2.55) relative to À1T allele carriers). Therefore, our results demonstrate a weak but significant association of the CD40À1(C,T) polymorphism with PF. The Kozak sequence includes the initiation codon (AUG) and surrounding nucleotides important for ribosome binding to the mRNA. 43 Changes in this sequence can cause major alterations in the initiation of translation. A significantly decreased CD40 translational (but not transcriptional) efficiency of the T allele, compared with the C allele, has been consistently demonstrated by different approaches. 42, 44 Thus, the presence of allele of CD40À1T is associated with a significant reduction of the gene product, mediated by a decrease in the efficiency of CD40 translation. Human keratinocytes express CD40, which may have a functional role in inflammatory skin disorders. 3 Recently, human CD40 was overexpressed in transgenic mice. Selective engagement of CD40 on the keratinocytes induced dendritic cell trafficking from the skin, amplified cutaneous immune responses and enhanced local T-cell responses. 45 Interestingly, there is an increased number of dendritic cells in endemic PF lesions and this correlates with serum antibody titers. 46 Thereby, according to the results of functional studies, the À1C allele may increase expression of CD40 on keratinocytes and contribute to the pathogenesis of PF. The consistency of the associations or trends observed for GD, MS and PF is compatible with a minor effect of the CD40 genetic variability on autoimmune disease susceptibility.
In respect to polymorphism À871C4T of the BLYS gene, a weak negative association was found with the T allele due to a decrease of both the T/T and T/C genotypes. The association in homo-and heterozygosity suggests a dominant protective effect of the T allele. A tendency for increase of the BLYS À871 T/T genotype was observed in a subgroup of SLE patients with anti-Sm antibodies and the BLYS mRNA level was significantly elevated in the monocytes from individuals having the À871T allele. 47 Elevated BLYS levels correlated with the presence of À871T was observed in patients with familial B-cell chronic lymphocytic leukemia as well. 48 The position À871 is located in the binding site of transcription factor MZF1, which was reported to be preferentially expressed in differentiating myeloid cells. 49 Thus, it is possible that this SNP may change the binding affinity of MZF1. 47 Further functional studies are necessary to clarify this possibility. Encouraging these studies is the fact that increased BLYS level was also observed in the serum or synovial fluid of human SLE, rheumatoid arthritis (RA) and Sjögren's syndrome. [11] [12] [13] The BLYS c.313G4A SNP is located in the coding region of the exon 1 and leads to an amino-acid substitution (Ala105Thr) within the extracellular region. The A allele (105Thr) was absent in control individuals and had very low frequencies in Japanese RA (0.9%) and SLE (0.3%) patients. 47 Because allele frequencies may differ among populations we decided to analyze this polymorphism in the Brazilian population. The frequency observed in our control sample (0.4%) was similar that to that found in the Japanese population. Owing to the low frequency of the minor allele, association analysis was not performed.
Regarding the CD19 gene, we analyzed two variations. The IVS14-30 C4T SNP within intron 14 and the 3 0 UTR(CA)n dinucleotide repeat were used as markers. Because 3 0 UTR sequences are involved in the regulation of translation or stability of mRNA, the 3 0 UTR microsatellite could have a direct effect on disease susceptibility. No significant associations or tendencies of IVS14-30 C4T polymorphism and PF were found. There is a positive association between the CD19 3 0 UTR 336 allele and the PF. Despite of the consistency of the statistical difference found for the CD19 3 0 UTR 336 allele in all subsamples analyzed, it would be premature to attribute a role for this polymorphism in disease pathogenesis because the samples of individuals carrying the 336 allele are very small. Lack of association of these two variations of the CD19 gene with RA and Chrohn's disease was reported. 50 However, the same authors showed that IVS14-30T was decreased in SLE patients and longer repeats (X15 times) of the 3 0 UTR(CA)n microsatellite were significantly increased in two independent groups of Japanese SLE patients. Despite the lack of statistical significance, the CD19 mRNA level was lower in the isolated peripheral blood B lymphocytes of individuals possessing longer repeats. As these two polymorphisms are in negative linkage disequilibrium in the Japanese population, Kuroki et al. 50 suggested that the 3 0 UTR polymorphism is most likely to have a primary functional effect because of the regulatory function of 3 0 UTR regions. The 3 0 UTR polymorphism presents linkage disequilibrium with the À499(G,T) SNP in the promoter region of the CD19 gene in the Japanese population. 51 These authors found an association of systemic sclerosis with these two polymorphisms and suggested that the À499(G,T) SNP has the primary function in the association with disease. The same variation in 3 0 UTR was not associated with SLE in a case-control study in Italy. 52 In our Brazilian population, alleles other than the most common one were rare, consistent with the results for Caucasian families from the United States. 50 These findings indicate that the allele frequencies of this STR differ among populations, and suggest the possibility that this polymorphism might be a risk factor in the Japanese, but not in European populations or populations of predominantly European ancestry. 50 We concluded that in the Brazilian population genetic variation of CD19 does not contribute significantly to disease risk or protection. However, it would be premature to conclude that CD19 variants have no function in PF pathogenesis. Alternatively, genetic variants of the CD19 gene may not influence disease susceptibility per se, but could have an effect in the clinical course of the disease. We propose that further studies should investigate the same and also other variants of the CD19 gene in larger samples and in different subgroups of patients: those who manifest the localized form and those with the generalized form of PF, in addition to those who respond to conventional therapy and those who do not.
A still unknown number of genes influence PF susceptibility but especially certain compound genotypes appear to alter the disease risk. We found clear-cut evidence of epistasis between some of the genes analyzed in this study. Gene-gene interactions are demonstrated because the effects of alleles (CD40À1T, BLYS À871T and CD40L À726C) are amplified by their coexistence in the same individual. The combined effect of CD40À1T and BLYS À871T and of CD40LÀ726C and BLYSÀ871T is stronger than the effect of any of these variants individually. In fact, some genotypes of one of these genes only influence the disease risk when occurring in combination with certain genotypes of the other gene(s). All SNPs here associated with PF are localized in 5 0 regulatory regions of the genes. Solid evidence for altered functional activity has thus far been demonstrated only for the CD40À1C4T SNP. However, modified transcriptional activity by the CD40LÀ726T4C and BLYSÀ871C4T SNPs is likely, because they are located in the binding sites of transcription factors, as commented above. Considering that CD40, CD40L and BLYS are molecules involved in B-cell proliferation, survival and response magnitude, our hypothesis is that higher expression of these molecules, related to the CD40LÀ726T, CD40À1C and BLYSÀ871C alleles, especially in homozygosis, can influence disease susceptibility to PF in two ways: (1) high levels of these gene products may cause B cells to escape the normal regulatory mechanism and mature into antibody-secreting B cells and plasma cells; (2) high levels could favor the phenomenon of epitope spreading in PF. It has been proposed that PF autoimmunity evolves from a nonpathogenic response to the fifth ectodomain (EC5) of dsg1 to a pathogenic response specific to the first two domains (EC1 and EC2) of this molecule. 19 In a first phase, an environmental antigen similar to the EC5 domain of dsg1 would elicit an antibody response to EC5 epitopes; in a second phase, in individuals having susceptible genotypes, intramolecular epitope spreading would lead to production of pathogenic antibodies against the EC1 and EC2 domains. It is possible that the susceptible compound genotypes of the B-cell costimulators might result in inappropriate longevity of autoreactive B cells, allowing autoantibody levels to reach pathogenic thresholds and contributing to breakdown of self-tolerance. Recently, it has been recognized that the CD40-CD40L system is upregulated both in lesional skin and in serum of patients with PF and vulgaris, another autoimmune bullous disease belonging to the pemphigus group. 53 Moreover, CD40-CD40L interactions can switch the immune response to the T H 2 pathway, the cytokine pattern prevalent in pemphigus lesional skin. 54 An incentive for further functional and association studies is the fact that there is a functional relationship between these gene products. In germinal centers, follicular dendritic cells express BLYS abundantly. BLYS may increase the ability of BCR to phosphorylate CD19. Moreover, upregulation of CD40 by BLYS renders the same B cells more susceptible to T-cell help by CD40L. Notably, colligation of BCR/CD19 without BLYS failed to upregulate CD40. 55 Besides, the blockade of the CD40-CD40L interaction by treatment with anti-CD40L monoclonal antibody inhibited the production of anti-Dsg3 IgG as well as the development of the pemphigus vulgaris disease phenotype in a mouse model. 6 In summary, our results reveal that CD40L, CD40 and BLYS are important genes modulating the susceptibility to endemic PF. Slight influence, like we saw for CD40À1C4T and BLYSÀ871C4T SNPs individually, is the rule in complex diseases. Therefore, it should be highlighted that the unusual strength and the consistency of the association found for the CD40LÀ726T4C SNP and PF is remarkable. The mechanisms accounting for the observed negative association remain to be clarified. Gene interaction analysis revealed that synergism of the CD40L, CD40 and BLYS genes leads some individuals to cross the threshold of disease manifestation, if they bear susceptibility alleles (polygenes) at other loci and are exposed to the putative nongenetic susceptibility factors.
To the best of our knowledge, this is the first association study between PF and these candidate genes and we hope that the results will stimulate further research looking for the possible role of these polymorphisms in disease pathogenesis.
Subjects and methods
Population sample A total of 179 patients and 317 healthy controls were enrolled in this study. The population studied is extensively admixed however not panmictic. Therefore, the different population strata may differ regarding allele frequencies. Considering the ensuing need of matching the patient and the control samples for ancestry, and the interest of association analysis in the subpopulations, individuals were classified according to an estimate of the relative contribution of European and African ancestry to each individual's genome, on the basis of information given by the individual. Two subsamples were obtained: Euro-Brazilian (EU; 106 patients and 246 controls), that is, of predominantly European origin and Afro-Brazilian (AF; 73 patients and 71 controls), that is, of mixed African and European origin. This approach to subdivide the population in strata according to ancestry has been validated by population genetics studies, which show that the distribution of alleles known to be restricted to populations autochthonous from one continent follows a gradient among the population strata, as expected if the classification discriminated the strata according to the relative contributions of the ancestral populations. 56, 57 Also according to these studies and to unpublished results of our group, the ancestry of the Afro-and the Euro-Brazilian population analyzed is 50 and 87% European, 44 and 8% African, and 6 and 5% Amerindian.
Patients were contacted and blood samples were collected at the Hospital Adventista do Pênfigo, in Campo Grande city, Mato Grosso do Sul state (n ¼ 132) and at the Hospital de Dermatologia Sanitária São Roque, in Piraquara city, Paraná state (n ¼ 47). PF diagnoses were based on clinical and histological criteria. Control samples were obtained in Campo Grande (n ¼ 176) and Curitiba city, Paraná state (n ¼ 141). Personal and clinical information was procured through a questionnaire and an interview. The control and patient groups were similar for birthplace and place of residence, socioeconomic status, gender prevalence, age distribution and occupation. All individuals were unrelated to each other. Informed consent was obtained. This study was approved by the Human Subjects Research Ethics Committee, as per Brazilian Federal laws.
Genotyping
The genotypes for the SNPs were determined by PCR-RFLP (PCR-restriction fragment length polymorphism) and PCR-SSCP (PCR-single strand conformation polymorphism) analyses. The STR (also known as microsatellites) were genotyped by PCR followed by fragment size analysis.
To genotype the CD40LÀ726T4C SNP (rs3092945), a 447 nucleotide pair fragment was amplified using the primers ATCTTCACAGCAACCTAC and CACTAAACT CAATGAAAGCC (5 0 -3 0 sequences). PCR was performed in a 12 ml reaction mixture containing 50 ng of genomic DNA, 0.6 mM of each primer, 200 mM of each dNTP, 2 mM MgCl 2 , 1 Â buffer and 0.5 U of Taq DNA polymerase. The PCR products were digested with the LewI (Fermentas, Glen Burnie, MD, USA) restriction endonuclease for 2 h at 37 1C and analyzed on a 3% agarose gel. The resulting fragments were 447 bp for the C/C genotype; 196 and 251 bp for the T/T genotype and 196, 251 and 447 bp for the T/C genotype.
The CD40-1C4T SNP (rs1883832) was genotyped according to Tomer et al., 35 with some adjustment of PCR conditions. PCR were performed in a 12 ml reaction mixture containing 50 ng of genomic DNA, 0.5 mM of the forward and reverse primers (5 0 -3 0 sequences CCTCTT CCCCGAAGTCTTCC and GAAACTCCTGCGCGGTGA AT, respectively), 200 mM each dNTP, 3 mM MgCl 2 , 1 Â buffer and 0.5 U of Taq DNA polymerase. PCR products (302 bp) were digested with 10 U of Eco130I (Fermentas) restriction enzyme; after 2 h incubation at 37 1C, electro-phoresis was performed in a 4% agarose gel. The restriction enzyme cleaves the PCR products at two sites, one of which is monomorphic, yielding a 99 bp fragment, whereas the other includes the SNP. Genotype assignments were based on the size of the resulting fragments, which were 99 and 203 bp for the T/T genotype; 99, 74 and 129 bp for the C/C genotype; and 99, 74, 129 and 203 bp for the T/C genotype.
The segment including the BLYSÀ871C4T SNP (rs9514828) was amplified using the primers GCAGTCA GGCATTTGGAGCTG and TGGGACTCATCACTGAAA CTCA (5 0 -3 0 sequences). PCR was performed in a 12 ml reaction mixture containing 60 ng of genomic DNA, 0.15 mM of each primer, 200 mM of each dNTP, 2 mM MgCl 2 , 1 Â buffer and 0.72 U of Taq DNA polymerase. The PCR products (162 bp) were digested with MbiI (Fermentas) restriction endonuclease for 2 h at 37 1C and analyzed on a 4% agarose gel. The resulting fragments were 162 bp for T/T genotype; 61 and 101 bp for C/C genotype; and 61, 101 and 162 bp for the T/C genotype.
The BLYS c.313G4A SNP (not registered) was genotyped using PCR-SSCP. PCR was performed in a 25 ml reaction mixture containing 80 ng of genomic DNA, 0.5 mM of each primer (5 0 -3 0 sequences AGTCACGCCTT ACTTCTTGC and AAGACGCAGGCAAGATCCT, respectively), 200 mM each dNTP, 2 mM MgCl 2 , 1 Â buffer and 1 U of Taq DNA polymerase. Six microlitres of the PCR products (351 bp) was mixed with 7 ml of a gel loading buffer in formamide and denatured for 5 min at 94 1C, quickly chilled on ice and analyzed on a 8% (acrylamide/bisacrylamide, 49:1) polyacrylamide gel supplemented with 5% glycerol. The gel polymerization was performed with 1% ammonium persulfate and TEMED 0.1%. Electrophoresis was run at 20 mA for 4 h. Following electrophoresis, the gels were stained with silver, according to the conditions described previously, 58 so the pattern could be visualized directly. DNA samples from individuals with different genotypes were gently provide by Dr N Tsuchiya and used as controls for correct genotype assignment.
The CD19 IVS14À30C4T SNP (rs60960563) was genotyped according to the strategy described by Kuroki et al. 50 PCR were performed in a 12 ml reaction mixture containing 50 ng of genomic DNA, 0.3 mM of the forward and reverse primers (5 0 -3 0 sequences GTGGCTACTGGC TTTCAGG and CCCCCAATGGCACTACTTC, respectively), 200 mM each dNTP, 2 mM MgCl 2 , 1 Â buffer and 0.5 U of Taq DNA polymerase. A 333 bp fragment was digested using the BamHI restriction endonuclease (Fermentas) and analyzed on a 3% agarose gel. The resulting fragments were 333 bp for the T/T genotype; 72 and 261 bp for the C/C genotype; and 72, 261 and 333 bp for the T/C genotype.
The STR are dinucleotide repeats and were genotyped by fragment size analysis. The PCR of the CD40L 3 0 UTR(CA) (rs56074249) and the CD19 3 0 UTR(CA) (rs28695658) microsatellites was carried out in the same reaction tube with 0.4 mM of each the forward fluorescent (FAM) and the reverse primers for CD40L (5 0 -3 0 sequences ACCCTCTCGGACAGTTATTC and GAAGA GAACTGACTAGCAACG, respectively) and the forward fluorescent (VIC) and the reverse primers for CD19 (5 0 -3 0 sequences GTGGCTACTGGCTTTCAGG and CCCCCA ATGGCACTACTTC, respectively) in a total volume of 10 ml containing 200 mM each dNTP, 2 mM MgCl 2 , 1Â buffer and 0.5 U of Taq DNA polymerase. The PCR products were denatured for 5 min at 94 1C and separated by size in a MegaBACE 1000 capilary array electrophoresis system (GE Healthcare, Pollards Wood, UK). Electropherograms were generated using the Fragment Profiler software 1.2 (GE Healthcare).
Statistical analysis
Genotypic, allelic and allele carrier frequencies (that is, number of individuals having the allele in either one or both chromosomes) were estimated by direct counting.
Comparisons of allele carrier, allelic and genotypic frequencies between the patient and control samples and between the EU and AF population strata were performed by analysis of 2 Â 2 contingency tables to calculate the exact probability (P) by the metropolis algorithm, using the RxC computational program (Flagstaff, AZ, USA). 59 To perform comparisons between genotypic frequencies, we arbitrarily adopted the most frequent genotype as reference (OR ¼ 1 by definition) and the frequencies of the other genotypes were compared to that genotype to estimate the respective OR. When the EU and AF population strata did not differ significantly, association analysis was also performed for the total population sample. When the two strata differed, we re-analyzed the merged sample after adjustment for the EU/AF disproportion.
Odds ratios were calculated by Woolf's method from the cross-product ratio of the entries in a 2 Â 2 contingency table with 95% CI. Hardy-Weinberg equilibrium was assessed using the method of Guo and Thompson 60 and included in the Arlequin software package version 3.11. 61 To identify possible interactions between alleles or genotypes at different unlinked loci, we performed stratified analysis according to Svejgaard and Ryder.
62 P ¼ 0.05 was considered as the significance limit for all comparisons.
Trying to not permit weak associations or tendencies to escape from our analysis, nominal P-values are reported to allow for proper interpretation and account for the explorative nature of association studies. 63, 64 Moreover, when the same associations are observed in independent population samples (EU and AF and, for CD40L, additionally the female and male strata), corrections for multiple testing are unnecessary.
